Three Stocks Rise from Pandemic’s Shadow: A Farce in Three Acts!

Ah, the hantavirus, that mischievous sprite of malady, hath once again stirred the pot of commerce! Behold, one mRNA juggernaut soared 36% from May’s depths, only to be humbled by profit-takers-how fickle the crowd! Thus reignited the pandemic-prep spectacle, three Covid-era stocks now prance anew upon the 2026 stage.

Each player dons a different mask. One boasts mRNA’s might, another masquerades as biodefense’s jester, the third, a contrarian fool brimming with bears. May 2026 shall decide their fates-will they bow or exit stage left?

Note: mRNA, that clever trick of science which instructs our cells without the bother of a live virus, as one might instruct a servant without lifting a finger oneself.

Moderna (NASDAQ: MRNA)

Of the returning thespians, Moderna took its bow first-a 36.08% leap from $43.69 to $59.45! Volume swelled like a chorus line, proving buyers, not shorts, drove the dance.

Thirsty for more? Subscribe to Harsh Notariya’s Daily Scribble-where finance meets farce!

Three musketeers spurred this rise: Q1 revenue vaulted 260% to $389 million; a hantavirus vaccine pact with the US Army (how timely!); and Phase 3 flu data published in the esteemed New England Journal of Medicine-a standing ovation!

$MRNA Q1 2026: Revenue’s Triumphant Return, Marred by a Trivial $878M Lawsuit

Modern delivered riches aplenty-$389M in revenue!-yet a paltry $878M settlement with Arbutus cast a shadow. One wonders if the lawyers’ fees outweighed the drama…

– Finsee (@Finsee_main) May 1, 2026

Now $MRNA lounges at $54.05, napping in a “cup-and-handle”-a pattern as delicate as a nobleman’s teacup grip. The cup’s base rests at $43.69, the rim near $59.45.

The handle flirts with the 20-day EMA (a trend oracle favoring recent whims) at $50.50.

Fail this cup, and the handle spills deeper than half its depth-shameful! The bullish thesis crumbles like a poorly baked tart.

Should $51.17 hold, all is well. Slip below, and the EMAs at $50.50 and $49.75 await. A plunge under $43.69? The pattern’s demise, most tragic.

A close above $54.91 heralds the handle’s breakout. Surpass $60.96 (neckline and Fibonacci’s blessing), and the stage is set for $81.46-33.59% gains! The crowd roars.

Moderna’s act concludes. Now, a smaller player (EBS) prepares its soliloquy.

Emergent BioSolutions (NYSE: EBS)

Once a star, now a cautionary tale: Emergent crafted J&J’s vaccine, till 2021’s contamination scandal ruined 15 million doses-a tragedy of Shakespearean proportions, though one suspects the bard would’ve added more poison and fewer spreadsheets.

Shares plunged 44.36% from $14.07 to $7.53 when 2026 guidance flopped below consensus. A second act of woe followed: Q1 revenue collapsed 30% to $156.1M-anthrax sales faltered, and even naloxone couldn’t save the day.

This second dip birthed an “inverse head-and-shoulders”-a pattern as hopeful as a suitor with a weak pulse. Left shoulder at $7.82, head at $7.53, right shoulder forming at $8.33-selling pressure wanes. Could the de-rating’s farce end?

Fail if the right shoulder sinks below the head-disaster! A close under $8.33 weakens the plot; below $7.53, the curtain falls.

Break above $10.02 (neckline and Fibonacci’s nod), and $12.65 beckons-a 25.76% gain. The prior high at $14.07? A dream too far, perhaps.

Emergent’s tale is set. Now, the contrarian’s delight awaits.

BioNTech (NASDAQ: BNTX)

BioNTech, co-creator of COMIRNATY with Pfizer, once raked in €18.98 billion-a golden age now faded. Since March, a “head-and-shoulders” pattern emerges: left shoulder at $100, head at $113.55, right shoulder at $93.63, near neckline $92.39.

The contrarian’s muse? Chaikin Money Flow-a proxy for institutional whims. Price fell, yet CMF rose since February 20-a divergence as suspicious as a monk with a hidden ledger.

Q1 brought a $2.28/share loss, revenue missed estimates, yet guidance held. Positioning? A put-call ratio so bearish it’d make a hibernating bear blush (2.23 by volume!). Short-squeeze potential, should $92.39 hold.

Below $92.39, $86.64 looms, then $79.31 and $72.36-the full tragic arc. Above $100.47, the right shoulder crumbles; $113.55 shattered, and the bearish mask slips.

Head-and-shoulders fails if the right shoulder bests the head-farce triumphs! For now, $92.39 guards the gates: a rebound or a plunge to $72.36. The crowd awaits the next act.

Read More

• USD JPY PREDICTION
• USD RUB PREDICTION
• USD AUD PREDICTION
• Gold Rate Forecast
• EUR CNY PREDICTION
• BCH PREDICTION. BCH cryptocurrency
• AAVE PREDICTION. AAVE cryptocurrency
• Hong Kong’s Strict Stablecoin Rules: Only 2 Licenses Out of 36 Applications Approved!
• XLM PREDICTION. XLM cryptocurrency
• SOL PREDICTION. SOL cryptocurrency

2026-05-12 23:25